The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

Magnesium sulfate (MgSO 4) has been explored as a potential treatment for acute asthma exacerbations, particularly in children. Its use is based on the premise that it may help relax the muscles ...

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® ...

A Phase II investigator-led trial investigating AstraZeneca’s Fasenra (benralizumab) treating eosinophilic exacerbations of ...

Asthma is a major noncommunicable disease, affecting both children and adults, and is the most common chronic disease among children, as per World Health Organization (WHO). The condition affected an ...

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

Oral corticosteroids, although effective, pose significant adverse effects and health care costs, necessitating clear tapering guidelines and alternative treatments. Biologics significantly reduce ...

Children who presented to the ED with severe asthma were eligible to enter the study. Severe asthma was classified as having all four features of respiratory distress (wheezing, sternal retraction, ...